Analysis on the Theory and Practice of Centralized Volume-Based Drug Procurement System in China

doi:10.19546/j.issn.1674-3830.2024.9.008

China Health Insurance ›› 2024, Vol. 0 ›› Issue (9) : 57-63. DOI: 10.19546/j.issn.1674-3830.2024.9.008

Observation & Discussion

Analysis on the Theory and Practice of Centralized Volume-Based Drug Procurement System in China

Author information +

History +

Abstract

In China, the centralized volume-based procurement of drugs is a system innovation that leverages the strategic purchasing function of healthcare insurance, to reconstruct the pharmaceutical price formation mechanism, standardize the order of drug circulation, reduce the burden of patients’ drug costs, and ensure rationality and safety of drug use. This study aims to systematically review the policy connotations, operational effects, and multi-influences from the perspective of system establishment. The core mechanism includes the working mechanism of government organization, alliance procurement, and platform operation, the rule mechanism of giving priority to drug quality, guaranteeing supply and procurement based on clinical needs, as well as the operation and maintenance mechanism of centralized procurement and use. The core drug price formation mechanism includes the market exchange mechanism of “price for volume” and market contract mechanism of “four guarantees” . The implementation of the system involves 4 key links (bidding procurement, supply and delivery, distribution and use, and continuation work) and 18 core elements. After the implementation of the centralized volume-based procurement policy, there were obvious clinical substitution effects of drug use, improvement in drug accessibility, significant decrease in drug costs which mainly benefits patients, increase in drug market concentration, and gradual reshaping of the industrial pattern.

Key words

centralized volume-based drug procurement system / price formation mechanism / policy effect

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Analysis on the Theory and Practice of Centralized Volume-Based Drug Procurement System in China[J]. China Health Insurance. 2024, 0(9): 57-63 https://doi.org/10.19546/j.issn.1674-3830.2024.9.008

References

[1] 毛宗福,崔丹,文小桐.药品集中带量采购制度[M]//中国药品供应保障制度概论.北京:社会科学文献出版社,2024:228-250.
[2] 蒋昌松,张立强,祁鹏,等.带量采购的部分经济学原理解析[J].卫生经济研究,2021,38(6):63-65.
[3] 胡善联. 带量采购的经济学理论基础和影响分析[J].卫生软科学,2019,33(1):3-5.
[4] 杨莹,毛宗福.医疗机构大数据与药物政策评价——以药品集中带量采购为例[M]//中国互联网医疗发展报告(2022—2023)——医疗健康大数据.北京:社会科学文献出版社,2023:67-85.
[5] LU J, LONG H, SHEN Y, et al.The change of drug utilization in China’s public healthcare institutions under the “4+7” centralized drug procurement policy: evidence from a natural experiment in China[J]. Frontiers in Pharmacology, 2022, 13: 923209.
[6] YANG Y, HU R, GENG X, et al.The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China[J]. The international journal of health planning and management, 2022, 37(3): 1650-1662.
[7] WANG J, YANG Y, XU L, et al.Impact of “4+7” volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China[J]. BMJ Open, 2022, 12(3): e054346.
[8] LUO N, YUE J, ZHOU R, et al.The effects of the National Drug Pooled Procurement (NDPP) pilot program in China[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 212-217.
[9] 蒋昌松.用数据说话:集采对产业发展影响几何? [EB/OL].(2022-09-21)[2024-06-25].https://new.qq.com/rain/a/20220921A08RYT00.
[10] 李大双,颜建周,白铭钰,等.国家组织药品集中采购供应问题及对策研究[J]. 卫生经济研究,2022,39(6):12-16.
[11] 刘雨欣,文小桐,段凤然,等.首批药品集采品种采购量变化的影响因素分析[J].中国药房,2024,35(6):641-646.
[12] 文小桐. 协同视角下药品集中带量采购对“医疗、医保、医药”的影响效应研究[D].武汉:武汉大学,2024.
[13] 文小桐,王越,段凤然,等.集采政策对不同等级公立医疗机构药品采购的影响[J].中国医疗保险,2023(3):32-40.
[14] 段凤然,文小桐,刘雨欣,等.国家药品集中带量采购政策下抗肿瘤药品使用特征分析[J].中国医疗保险,2023(5):104-109.
[15] 段凤然,文小桐,王越,等.集采政策对医疗机构心血管药品采购的影响研究[J].卫生经济研究,2024,41(3):69-73.
[16] 杨莹. 战略性购买视角下我国药品集中带量采购政策对药品价格与费用的影响研究[D].武汉:武汉大学,2022.
[17] 张雨薇,王莉.我国国家药品集中采购政策实施效果的系统评价[J].医学与社会,2023,36(3):119-124.
[18] 李玉水,康洽福,韩雅清,等.药品带量采购对患者医疗负担的政策效应研究[J].卫生经济研究,2021,38(4):28-32.
[19] LAN T, GUAN L, PANG X, et al.Impact of the National Centralized Drug Procurement Policy (4+7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: a single centre, interrupted time series[J]. Journal of clinical pharmacy and therapeutics, 2022, 47(1): 104-111.
[20] 陈维雄,夏锋,陈泽波,等.“4+7”政策对广州市公立医院住院患者费用的影响[J].中国药物经济学,2021,16(7):13-17+23.
[21] 申芳丽,刘璐,宋沧桑,等.国家药品集采实施效果与评价——以某三甲医院为例[J].中国医疗保险,2021(8):57-60.
[22] LONG H, YANG Y, GENG X, et al.Changing characteristics of pharmaceutical prices in China under centralized procurement policy: a multi-intervention interrupted time series[J]. Frontiers in pharmacology, 2022, 13: 944540.
[23] 王彪,张天天,唐啸宇,等.国家组织药品带量采购政策的降价持续性研究[J].中国卫生政策研究,2023,16(4):32-36.
[24] 陈文,蒋虹丽,龚波,等.上海市药品采购价格和采购量指数编制及应用分析[J].中国卫生经济,2023,42(9):11-15.
[25] YANG Y, LIU Y, MAO Z, et al.The impact of Chinese volume-based procurement on pharmaceutical market concentration[J]. Frontiers in pharmacology, 2024, 15: 1386533.
[26] 王越,文小桐,段凤然,等.集采政策对制药企业在公立医疗机构药品销售的影响——以首批国家集采药品为例[J].中国医疗保险,2023(9):106-112.
[27] 文小桐,刘雨欣,王越,等.集采对公立医疗机构不同中标情况药品采购的影响[J].中国医疗保险,2023(4):4-11.
[28] 普华永道. 2019年中国企业并购市场回顾与2020年展望——医药和生命科学行业[R]. 2020.
[29] 孙言,朱正,杨莉.国家组织药品集中带量采购价格降幅影响因素分析[J].中国卫生政策研究,2022,15(2):54-59.
[30] 杨莹,刘雨欣,毛靖,等.药品集中带量采购政策对我国医药产业的影响——基于SCP范式的综述研究[J].中国卫生政策研究,2023,16(12):40-48.
[31] 毛宗福,沈晓,王全.我国医疗机构药品集中采购工作回顾性研究[J].中国卫生政策研究,2014,7(10):5-10.
[32] 毛宗福,陈磊,杨莹.药品供应保障制度改革措施与效果分析[M]//中国医改发展报告(2020).北京:社会科学文献出版社,2020:96-123.
[33] 毛宗福,陈磊,杨莹.国家组织药品集中采购和使用试点的价值与思考[EB/OL].(2019-10-18)[2024-06-08].http://news.cctv.com/2019/10/18/ARTIjbiaVFHZrIpaByOzjFPy191018.shtml.
[34] 蒋昌松,祁鹏,郭丹.我国药品集中采购制度历史变迁及改革发展趋势[J].中国医疗保险,2022(4):5-11.
[35] 毛宗福,王欣,孙静.药物流行病学与药物政策[M]//药物流行病学(第2版).北京: 中国医药科技出版社,2016.